Abstract
Cutaneous malignant melanoma (CMM) is a potentially fatal form of skin cancer whose incidence is rising in many regions of the world [1–4]. Data from the Scottish Melanoma Group showed that in Scotland the incidence of CMM increased 82% over an 11-year period from 3.4 per 100 000 in 1979 to 7.1 per 100 000 in 1989 for men and from 6.6 per 100 000 to 10.4 per 100 000 for women [4]. In Queensland, Australia, which has the highest incidence of cutaneous melanoma in both men and women, the cumulative risks of invasive melanoma have increased to 1 in 19 for men and to 1 in 25 for women. The incidence of CMM increased from 25.3 per 100 000 in 1979–1980 to 55.8 per 100 000 in 1987 for men and from 27.1 per 100 000 to 42.9 per 100 000 in women [1]. In the US, over the period 1973–1990, the incidence of malignant melanoma among whites increased nearly 95%, more than that of any other cancer. The overall age-adjusted incidence rate of invasive melanoma for 1986–1990 was 10.9 per 100 000, 12.1 per 100 000 in whites and 0.8 per 100 000 in blacks. For white men, the overall age-adjusted incidence was 14.1 per 100 000, and for white women, 10.6 per 100 000 [3].
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
MacLennan, R., Green, A.C., McLeod, G.R.C. and Martin, N.G. (1992) Increasing incidence of cutaneous melanoma in Queensland. Australia. J. Natl Cancer Inst., 84, 1427–32.
Osterlind, A., Hou-Jensen, K. and Moller Jensen, O. (1988) Incidence of cutaneous malignant melanoma in Denmark 1978-1982. Anatomic site distribution, histologic types, and comparison with non-melanoma skin cancer. Br. J. Cancer, 58, 385–91.
Miller, B.A., Gloeckler Ries, L.A., Hankey, B.F. et al. (eds) (1993) Cancer Statistics Review 1973-1990. US Department of Health and Human Services, NIH Publication No. 93-2789.
MacKie, R., Hunter, J.A.A., Aitchison, T.C. et al. (1992) Cutaneous malignant melanoma, Scotland, 1979-89. Lancet, 339, 971–5.
Greene, M.H. and Fraumeni, J.F. Jr (1979) The Hereditary Variant of Malignant Melanoma, Grune and Stratton, New York.
Tucker, M. A. (1988) Individuals at high risk of melanoma. Pigment Cell, 9, 95–109.
Osterlind, A., Tucker, M.A., Stone, B.J. and Jensen, O.M. (1988) The Danish case-control study of cutaneous malignant melanoma II. Importance of UV-light exposure. Int. J. Cancer, 42, 319–24.
Zanetti, R., Franceschi, S., Rosso, S. et al. (1992) Cutaneous melanoma and sunburns in childhood in a Southern European population. Eur. J. Cancer, 28A, 1172–6.
Holly, E.A., Kelly, J.W., Shpall, S.N. and Chiu, S.-H. (1987) Number of melanocytic nevi as a major risk factor for malignant melanoma. J. Am. Acad. Dermatol., 17, 459–68.
Swerdlow, A.J., English, J., MacKie, R.M. et al. (1986) Benign melanocytic naevi as a risk factor for malignant melanoma. Br. Med. J., 292, 1555–9.
Reimer, R.R., Clark, W.H. Jr, Greene, M.H. et al. (1978) Precursor lesions in familial melanoma: a new genetic preneoplastic syndrome. JAMA, 239, 744–6.
Greene, M.H., Clark, W.H. Jr, Tucker, M.A. et al. (1985) Acquired precursors of cutaneous malignant melanoma: the familial dysplastic nevus syndrome. N. Engl. J. Med., 312, 91–7.
Tucker, M.A., Fraser, M.C., Goldstein, A.M. et al. (1993) The risk of melanoma and other cancers in melanoma-prone families. J. Invest. Dermatol., 100, S350–5.
Halpern, A.C., Guerry, D. IV, Elder, D.E. et al. (1991) Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. Arch. Dermatol., 127, 995–9.
Rousch, G.C., Nordlund, J.J., Forget, B., et al. (1988) Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev. Med., 17, 273–9.
Goldstein, A.M., Fraser, M.C. and Tucker, M.A. (1993) Risk factors for familial melanoma. Am. J. Hum. Genet., 53 (Suppl.), 808.
Elwood, J.M., Whitehead, S.M., Davison, J. et al. (1990) Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour, and sunburn. Int. J. Epidemiol. 19, 801–10.
Osterlind, A., Tucker, M.A., Hou-Jensen, K. et al. (1988) The Danish case-control study of cutaneous melanoma. I. Importance of host factors. Int. J. Cancer, 42, 200–6.
Barnhill, R.L., Rousch, G.C. and Titus-Ernstoff, L. (1992) Comparison of nonfamilial and familial melanoma. Dermatology, 184, 2–7.
Kopf, A.W., Hellman, L.J., Rogers, G.S. et al. (1986) Familial malignant melanoma. JAMA, 256, 1951–9.
Kefford, R.F., Salmon, J., Shaw, H.M. et al. (1991) Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet. Cytogenet., 51, 45–55.
Li, F.P., Fraumeni, J.F.-Jr, Mulvihill, J.J. et al. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res., 48, 5358–61.
Lynch, H.T., Fusaro, R.M., Kimberling, K.J. et al. (1983) Familial atypical multiple mole melanoma (FAMMM) syndrome: segregation analysis. J. Med. Genet., 20, 342–4.
Bergman, W., Watson, P., deJong, J. et al. (1990) Systemic cancer and the FAMMM syndrome. Br. J. Cancer, 61, 932–6.
Goldstein, A.M., Fraser, M.C., Struewing, J.P. et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med., 333, 970–4.
NIH Consensus Statement: Diagnosis and treatment of early melanoma. NIH Consensus Development Conference, January 27-29, 1992, Vol.10, no. 1.
Clark, W.H. Jr, Elder, D.E., Guerry, D. IV et al. (1989) Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst., 81, 1893–904.
Tokar, I.P., Fraser, M.C. and Bale, S.J. (1992) Genodermatoses with profound malignant potential. Semin. Oncol. Nursing, 8, 272–80.
Mackie, R.M., McHenry, P. and Hole, D. (1993) Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet, 341, 1618–20.
Masri, G.D., Clark, W.H. Jr, Guerry, D. IV et al. (1990) Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J. Am. Acad. Dermatol., 22, 1042–8.
Crutcher, W.A. and Cohen, P.J. (1990) Dysplastic nevi and malignant melanoma. Am. Family Physician, 42, 372–85.
Friedman, R.J., Rigel, D.S., Silverman, M.K. et al. (1991) Malignant melanoma in the 1990’s: the continued importance of early detection and the role of physician and self-examination of the skin. Cancer J. Clin., 41, 201–26.
Halpern, A.C., Guerry, D. IV, Elder, D.E. et al. (1993) Natural history of dysplastic nevi. J. Am. Acad. Dermatol., 29, 51–7.
Young, J.L., Percy, C.L. and Asire, A.J. (eds) (1981) Surveillance, Epidemiology, and End Results: Incidence and Mortality Data 1973-77. NIH Publication 81-2330, Department of Health and Human Services, Bethesda, MD.
National Cancer Institute. NIH. US Department of Health and Human Services. (1990) What you need to know about dysplastic nevi. NIH Publication No. 91-3133.
Fountain, J.W., Bale, S.J., Housman, D.E. and Dracopoli, N.C. (1990) Genetics of melanoma. Cancer Surv., 9, 645–71.
Bale, S.J., Dracopoli, N.C, Tucker, M.A. et al. (1989) Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N. Engl. J. Med., 320, 1367–72.
van Haeringen, A., Bergman, W., Nelen, M.R. et al. (1989) Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics, 5, 61–4.
Cannon-Albright, L.A., Goldgar, D.E., Wright, E.C. et al. (1990) Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Am. J. Hum. Genet., 46, 912–8.
Nancarrow, DJ., Palmer, J.M., Walters, N.K. et al. (1992) Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm lp in 7 Australian pedigrees. Genomics, 12, 18–25.
Goldstein, A.M., Dracopoli, N.C, Ho, E.C. et al. (1993) Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome lp and evidence for genetic heterogeneity. Am. J. Hum. Genet., 52, 537–50.
Hawkins, B.R., Dawkins, R.L., Hockey, A. et al. (1981) Evidence for linkage between HLA and malignant melanoma. Tissue Antigens, 17, 540–1.
Pellegris, G., Illeni, M.T., Rovini, D. et al. (1982) HLA complex and familial malignant melanoma. Int. J. Cancer, 29, 621–3.
Demenais, F., Cesarini, J.P., Daveau, M. et al. (1984) A linkage study between HLA and cutaneous malignant melanoma or precursor lesions or both. J. Med. Genet., 21, 429–35.
Mueller-Eckhardt, G., Schendel, D.J., Hundeiker, M. et al. (1984) Possible association between HLA-DR5 and superficial spreading melanoma (SSM). Int. J. Cancer, 34, 751–5.
Bale, S.J., Greene, M.H., Murray, C. et al. (1985) Hereditary malignant melanoma is not linked to the HLA complex on chromosome 6. Int. J. Cancer, 36, 439–43.
Cowan, J.M., Halaban, R. and Francke, U. (1988) Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J. Natl Cancer Inst., 80, 1159–64.
Dracopoli, N.C., Alhadeff, B., Houghton, A.N. and Old, L. J. (1987) Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. Cancer Res., 47, 3995–4000.
Petty, E.M., Gibson, L.H., Fountain, J.W. et al. (1993) Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor suppressor gene(s). Am. J. Hum. Genet., 53, 96–104.
Pedersen, M.I. and Wang, N. (1989) Chromosomal evolution in the progression and metastasis of human malignant melanoma. Cancer Genet. Cytogenet., 41, 185–201.
Fountain, J.W., Karayiorgou, M., Ernstoff, M.S. et al. (1992) Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl Acad. Sci. USA, 89, 10557–61.
Cannon-Albright, L.A., Goldgar, D.E., Meyer, L J. et al. (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science, 258, 1148–52.
Nancarrow, D.J., Mann, G.J., Holland, E.A. et al. (1993) Confirmation of chromosome 9p linkage in familial melanoma. Am. J. Hum. Genet., 53, 936–42.
Goldstein, A.M., Dracopoli, N.C., Engelstein, M. et al. (1994) Linkage of cutaneous malignant melanoma/dysplastic nevus (CMM/DN) to chromosome 9p and evidence for genetic heterogeneity. Am. J. Hum. Genet., 54, 489–96.
Serrano, M., Hannon, G.J. and Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature, 366, 704–7.
Kamb, A., Gruis, N.A., Weaver-Feldhaus, J. et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436–40.
Nobori, T., Miura, K., Wu, D.J. et al. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753–6.
Hussussian, C.J., Struewing, J.P., Goldstein, A.M. et al. (1994) Germline p16 mutations in familial melanoma. Nature Genet., 8, 15–21.
Kamb, A., Shattuck-Eidens, D., Eeles, R. et al. (1994) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet., 8, 22–6.
MacGeoch, C, Newton Bishop, J.A., Bataille, V. et al. (1994) Genetic heterogeneity in familial malignant melanoma. Hum. Mol. Genet., 3, 2195–200.
Gruis, N.A., van der Velden, P.A., Sandkuijl, L.A., et al. (1995) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet., 10, 351–3.
Ohta, M., Nagai, H., Shimizu, M. et al. (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res., 54, 5269–272.
Liu, L., Lassam, N.J., Slingerland, J.M. et al. (1995) Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene, 11, 405–12.
Walker, G.J., Hussussian, C.J., Flores, J.F. et al. (1995) Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum. Mol. Genet., 4, 1845–52.
Ranadi, K., Hussussian, C.J., Sikorski, R.S. et al. (1995) Mutations associated with familial melanoma impair p16INK4 function. Nature Genet., 10, 114–16.
Millikin, O., Meese, E. and Vogelstein, B. (1991) Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res., 51, 5449–53.
Parmiter, A.H. and Nowell, P.C. (1993) Cytogenetics of melanocytic tumors. J. Invest. Dermatol., 100, S254–8.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Goldstein, A.M., Tucker, M.A. (1996). Familial melanoma and its management. In: Eeles, R.A., Ponder, B.A.J., Easton, D.F., Horwich, A. (eds) Genetic Predisposition to Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-4501-3_23
Download citation
DOI: https://doi.org/10.1007/978-1-4899-4501-3_23
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-412-56580-9
Online ISBN: 978-1-4899-4501-3
eBook Packages: Springer Book Archive